[go: up one dir, main page]

PT2111868E - Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos - Google Patents

Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos

Info

Publication number
PT2111868E
PT2111868E PT83803015T PT08380301T PT2111868E PT 2111868 E PT2111868 E PT 2111868E PT 83803015 T PT83803015 T PT 83803015T PT 08380301 T PT08380301 T PT 08380301T PT 2111868 E PT2111868 E PT 2111868E
Authority
PT
Portugal
Prior art keywords
drug
preparation
treatment
patients suffering
cognitive disorders
Prior art date
Application number
PT83803015T
Other languages
English (en)
Inventor
Victor Grifols Roura
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of PT2111868E publication Critical patent/PT2111868E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT83803015T 2007-10-26 2008-10-22 Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos PT2111868E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Publications (1)

Publication Number Publication Date
PT2111868E true PT2111868E (pt) 2013-10-17

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
PT83803015T PT2111868E (pt) 2007-10-26 2008-10-22 Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos

Country Status (16)

Country Link
US (1) US7851446B2 (pt)
EP (1) EP2111868B1 (pt)
JP (1) JP5437619B2 (pt)
CN (1) CN101417123B (pt)
AR (1) AR068901A1 (pt)
AU (1) AU2008233025B8 (pt)
BR (1) BRPI0804623B8 (pt)
CA (1) CA2641830C (pt)
CL (1) CL2008003133A1 (pt)
ES (2) ES2332846B1 (pt)
MX (1) MX2008013635A (pt)
NZ (1) NZ572131A (pt)
PL (1) PL2111868T3 (pt)
PT (1) PT2111868E (pt)
RU (1) RU2414925C2 (pt)
UY (1) UY31418A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
WO2018034712A1 (en) * 2016-08-18 2018-02-22 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CA3105956A1 (en) * 2018-07-20 2020-01-23 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
CN119345230A (zh) 2018-10-26 2025-01-24 万能溶剂有限公司 血浆和血浆组分用于改善疼痛的用途
CN116406374A (zh) 2020-10-30 2023-07-07 深圳普罗吉医药科技有限公司 人血清白蛋白在治疗疾病中的应用
MX2023011872A (es) * 2021-04-30 2023-10-17 Grifols Worldwide Operations Ltd Uso de recambio plasmatico terapeutico y recambio plasmatico de bajo volumen para el tratamiento de un deterioro cognitivo.
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
WO2001090758A2 (en) 2000-05-23 2001-11-29 The University Of Southern California Diagnosis of alzheimer's disease ldl receptor protein-1
EP1370240A4 (en) * 2001-03-02 2004-09-22 Neuron Therapeutics Inc NEUROPROTECTOR FORMULATIONS AND METHOD
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
KR101122782B1 (ko) 2002-10-04 2012-04-12 프라나 바이오테크놀로지 리미티드 신경 활성 화합물
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
KR20050103292A (ko) 2003-02-13 2005-10-28 옥타파르마 아게 알부민 용액 및 이의 제조 방법
AU2004311577A1 (en) 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
RU2261702C1 (ru) * 2004-09-23 2005-10-10 Смирнов Алексей Владимирович Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией
RU2281090C2 (ru) * 2004-09-23 2006-08-10 Алексей Владимирович Смирнов Способ лечения больных хронической почечной недостаточностью
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
RU2414925C2 (ru) 2011-03-27
CA2641830A1 (en) 2009-04-26
CN101417123A (zh) 2009-04-29
PL2111868T3 (pl) 2014-01-31
AU2008233025A1 (en) 2009-05-14
AU2008233025B2 (en) 2013-06-27
CN101417123B (zh) 2012-06-27
JP5437619B2 (ja) 2014-03-12
JP2009108059A (ja) 2009-05-21
CA2641830C (en) 2013-07-16
US7851446B2 (en) 2010-12-14
BRPI0804623A2 (pt) 2009-06-30
AU2008233025B8 (en) 2013-07-25
MX2008013635A (es) 2009-05-11
CL2008003133A1 (es) 2009-08-07
ES2332846A1 (es) 2010-02-12
UY31418A1 (es) 2009-05-29
RU2008141076A (ru) 2010-04-27
AR068901A1 (es) 2009-12-16
BRPI0804623B8 (pt) 2021-05-25
ES2428698T3 (es) 2013-11-08
HK1126689A1 (en) 2009-09-11
US20090111740A1 (en) 2009-04-30
ES2332846B1 (es) 2010-07-08
NZ572131A (en) 2010-06-25
EP2111868A1 (en) 2009-10-28
BRPI0804623B1 (pt) 2020-02-11
EP2111868B1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
JP2022009125A5 (pt)
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
JP2006501240A5 (pt)
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
WO2008066856A3 (en) Patient specific ankle-foot orthotic device
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
PT2210605T (pt) Formas de dosagem única diária de tróspio
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
WO2008067991A3 (en) Skin-friendly drug complexes for transdermal administration
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
WO2006129304A3 (en) Pulsating inhaler and a method of treating upper respiratory disorders
MY135838A (en) Methods for the treatment of mental disorders
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
EP1728076A4 (en) SYSTEM AND METHOD FOR PROVIDING OPTIMUM CONCENTRATIONS FOR MEDICAMENT INFUSIONS
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
EP2545929A4 (en) Means for the alleviation or cure of chronic prostatitis, interstitial cystitis or bladder-weaning disorders
KR101874951B1 (ko) 립실 테이프
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
DE602007014193D1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
RU2006101061A (ru) Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела
CN201295460Y (zh) 医用供药口罩
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
NZ599227A (en) Therapeutic agent for chronic pain